Everything You Need
to Know About DermaSensor
Explore how DermaSensor helps physicians assess suspicious skin lesions with immediate, objective, AI-powered results. Download materials to learn about the technology, clinical evidence, workflow integration, and practice benefits.
Explore peer-reviewed research articles and clinical studies on DermaSensor technology for non-invasive skin cancer detection.
-
Elastic Scattering Spectroscopy (ESS) Tissue Analysis
Read MoreDermaSensor uses ESS technology to analyze microscopic tissue characteristics beneath the skin surface. By measuring how light reflects off cellular structures, the technology captures optical signals associated with histopathological features of malignancy, such as nucleus size, the presence of condensed chromatin, and melanocyte density. No imaging, biopsies, or invasive methods are required.
-
DermaSensor Product Brochure
Read MoreDermaSensor empowers physicians by providing objective, actionable risk results to aid in skin cancer detection by assessing cellular and sub-cellular
features that cannot be seen visually or dermoscopically. -
Summary of DermaSensor Device Safety and Effectiveness Results From Three Clinical Studies
Read MoreSummary of DermaSensor Safety and Effectiveness
Results From Three Clinical Studies
FDA Cleared -
Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physicians’ Detection of Skin Cancers
View moreElizabeth V Seiverling, MD1 ; Thomas Agresta, MD, MBI2 ; Peggy Cyr, MD3 ; Laurie Caines, MD4 ; Vivien L Nguyen, PharmD6 ; Kiran Chatha, MD, MPH6 ; Daniel M Siegel, MD5
1Tufts University School of Medicine, Boston, MA; 2University of Connecticut School of Medicine, Farmington, CT; 3Maine Medical Partners Family Medicine, Portland, ME; 4UConn Health, Farmington, CT; 5SUNY Downstate Health Sciences University, Brooklyn, NY; 6DermaSensor, Inc., Miami, FL
FDA Cleared. Available in the United States. -
Clinical Performance of Novel Elastic Scattering Spectroscopy (ESS) in Detection of Skin Cancer: A Blinded, Prospective, Multi-Center Clinical Trial
Learn MoreStephen P Merry, MD1; Brian McCormick, MD2; Vivien Nguyen PharmD4, Kiran Chatha, MD, MPH4; Ivana Croghan, PhD1,, David Leffell, MD3
1 Mayo Clinic, Rochester, MD; 2 Hampton Family Practice, Hampton, VA; 3 Yale School of Medicine, New Haven, CT; 4 DermaSensor Inc.
FDA Cleared.
Available in the United States. -
Validation of a Handheld Elastic Scattering Spectroscopy Device on Lesions Concerning for Melanoma
Read MoreRebecca Hartman, MD MPH1; Uwe Paasch MD2; Kelly Tepedino MD3, Max Fung MD4, Jennifer McNiff MD5, Jane Grant-Kels MD6
1 Brigham and Women’s Hospital, USA; 2 University of Leipzig; Germany 3 North Florida Dermatology, USA; 4 University of California, USA; 5 Yale University, USA 6 University of Connecticut, USA
FDA Cleared. Available in the United States.
